jRCT2031240321招募中不适用
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase (CLNP023Q12301)
Novartis Pharma. K.K.0 个研究点目标入组 12 人开始时间: 2024年9月25日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 75age old not（—）
- 性别
- All
入选标准
- •Adult patients with generalized Myasthenia Gravis (age 18-75 years)
- •Positive serology testing for AChR+ antibody at screening
- •Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG and likely not in need of a respirator for the duration of the study, as judged by the Investigator.
- •The confirmation of the diagnosis of gMG should be documented and supported by =>1 of the following 3 tests:
- •History of abnormal neuromuscular transmission demonstrated by single-fiber electromyography or repetitive nerve stimulation.
- •History of positive edrophonium chloride test
- •Patient has demonstrated improvement in MG signs on oral acetylcholinesterase inhibitors as assessed by the treating physician.
- •Baseline MG-ADL score =>6, with =>50% of the total score due to non-ocular symptoms
- •Participants not optimally controlled for =>6 months on
- •just one NSIST; or
- •two or more NSISTs; or
- •on frequent (at least quarterly) plasmapheresis, plasma exchange, or intravenous immunoglobulin to control symptoms despite treatment with steroids and NSISTs; or
- •one of the following gMG treatments:
- •a FcRN antagonist approved for gMG
- •rituximab
- •other approved gMG therapies excluding complement inhibitors.
- •Consistent with all other iptacopan trials, participants will have to be vaccinated against Neisseria meningitidis and Streptococcus pneumoniae. In addition, participants will be vaccinated against Haemophilus influenzae, depending on the local regulations and on the availability of this vaccine in the countries of study conduct. The vaccination will be performed at least 2 weeks prior to first dosing with iptacopan, covering as many serotypes as possible. If iptacopan treatment will start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment must be initiated and administered until 2 weeks post vaccination.
排除标准
- •Have been treated with intravenous immunoglobulin (IVIG)/plasma exchange (PLEX) in the past month, with rituximab in the past 6 months, eculizumab in the past 2 months, ravulizumab or other complement inhibitors in the past 3 months, efgartigimod or other anti-FcRn therapies in the past 3 months, or had a thymectomy in the past 6 months or a planned thymectomy during the trial period.
- •Participants with clinically significant active or chronic uncontrolled bacterial, viral, or fungal infection at screening, including patients who test positive for an active viral infection at screening with: Active Hepatitis B Virus (HBV): serologic panel test results indicative of an active (acute or chronic) infection; Active Hepatitis C Virus (HCV): serology positive for HCV-Ab; Human Immunodeficiency Virus (HIV) positive serology associated with an Acquired Immune Deficiency Syndrome (AIDS)-defining condition or with a cluster of differentiation 4 (CD4) count =<200 cells/mm3
- •Female participants who are pregnant or lactating, or are intending to become pregnant.
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.
- •Active systemic bacterial, viral (including COVID-19) or fungal infection or any major episode of infection that required hospitalization or injectable antimicrobial therapy within 14 days prior to study drug administration.
- •History of recurrent invasive infections caused by encapsulated organisms, e.g., N. meningitidis and S. pneumoniae.
- •Presence of fever =>38 degree Celsius (100.4 degree Fahrenheit) within 7 days prior to study drug administration
结局指标
主要结局
-
Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura. - The use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura.Thrombotic Thrombocytopenia PurpuraEUCTR2005-002274-30-GBniversity College London40
招募中
不适用
A study to evaluate the efficacy, safety, and tolerability of remibrutinib tablets compared with placebo tablets in patients aged 18 to 75 with generalized Myasthenia Gravis who are receiving standard treatment. (CLOU064O12301)jRCT2021250004Novartis Pharma. K.K.14
未知
3 期
To Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian MedicationsJPRN-jRCT2080222381AbbVie GK32
进行中（未招募）
1 期
A Study to Assess the Efficacy, Safety and Pharmacokinetics of IONIS SMNRx in Infants With Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)EUCTR2017-000621-12-Outside-EU/EEAIonis Pharmaceuticals, Inc.20
招募中
2 期
Photodynamic diagnosis by LED endoscopy systemAlimentary canal tumorJPRN-jRCTs061200034Isomoto Hajime60